Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models

…, BW Camp, HA Bimonte-Nelson, J Bode… - Journal of …, 2012 - Soc Neuroscience
M 1 muscarinic acetylcholine receptors (mAChRs) represent a viable target for treatment of
multiple disorders of the central nervous system (CNS) including Alzheimer's disease and …

The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A …

…, S Jadhav, DW Engers, K Italiano, J Bode… - … of Pharmacology and …, 2012 - ASPET
Parkinson's disease (PD) is a debilitating neurodegenerative disorder associated with
severe motor impairments caused by the loss of dopaminergic innervation of the striatum. …

[HTML][HTML] The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling

GJ Kaczorowski, ML Garcia, J Bode, SD Hess… - Frontiers in …, 2011 - frontiersin.org
Profiling of putative lead compounds against a representative panel of relevant enzymes,
receptors, ion channels, and transporters is a pragmatic approach to establish a preliminary …

The mGlu4 positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine A2A antagonist in preclinical rodent …

…, S Jadhav, DW Engers, K Italiano, J Bode… - … of Pharmacology and …, 2011 - ASPET
Parkinson9s disease (PD) is a debilitating neurodegenerative disorder associated with
severe motor impairments caused by the loss of dopaminergic innervation of the striatum. …

Affinity purification of a chimeric nicotinic acetylcholine receptor in the agonist and antagonist bound states

S Liu, MS Babcock, J Bode, JS Chang… - Protein Expression and …, 2011 - Elsevier
Nicotinic acetylcholine receptors (nAChRs) form ligand-gated ion channels that mediate fast
signal transmission at synapses. These receptors are members of a large family of …

Development of high throughput flow cytometry assays to support target therapy/personalized medicine in oncology drug discovery and development: Developing and …

Z Feng, T Baginski, M Donio, D Werth, J Bode - Cancer Research, 2014 - AACR
Background: Pharmacodynamics (PD) endpoint assays are important biomarker(s) for target
therapy/personalized medicine in oncology drug discovery & development. Identification of …

Combining large scale biochemical and cellular profiling data to better understand the mechanism of anti-tumor drugs

S Nauman, J Bode, C Hadden, L Byers, BN Armbruster - Cancer Research, 2011 - AACR
This study was designed to elucidate the selectivity and cellular behavior of several marketed
kinase inhibitors used in the treatment of cancer patients. Generally, kinase inhibitors are …

Scanning electron microscope (SEM) studies on the epiblast of young chick embryos

HJ Jacob, B Christ, M Jacob, GJ Bijvank - Zeitschrift für Anatomie und …, 1974 - Springer
The epiblast of young chick embryos of stages 4–8 (Hamburger and Hamilton) was investigated
by scanning electron microscopy. On the basis of surface differentiation, two zones can …

[HTML][HTML] Crystal structure of gingipain R: an Arg‐specific bacterial cysteine proteinase with a caspase‐like fold

A Eichinger, HG Beisel, U Jacob, R Huber… - The EMBO …, 1999 - embopress.org
Gingipains are cysteine proteinases acting as key virulence factors of the bacterium
Porphyromonas gingivalis, the major pathogen in periodontal disease. The 1.5 and 2.0 Å crystal …

[PDF][PDF] The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases

…, U Jacob, R Huber, A Wisner, C Bon, W Bode - Structure, 1998 - cell.com
Background: Trimeresurus stejnejeri venom plasminogen activator (TSV-PA) is a snake
venom serine proteinase that specifically activates plasminogen. Snake venom serine …